Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Sequential Azacitidine and High-Dose Lenalidomide for Relapsed and Refractory High-Risk MDS and AML: Interim Analysis of a Phase 2 Study

Daniel A Pollyea, Clayton A. Smith, MD FRCPC, Vu H. Nguyen, MD, Aaron Fullerton, MBS, Derek Schatz, BS, Edward J Bedrick, PhD, Jonathan A Gutman, MD

Blood (2014) 124 (21): 3746.

https://doi.org/10.1182/blood.V124.21.3746.3746

Published: 2014

Journal Articles

Selected Commensals Mediate GvHD Via MyD88-Dependent Signaling in Non-Hematopoietic Cells.

Matthew Horch, Nathanael Sahli, Elizabeth Zale, Kyle Tretina, Vu H. Nguyen, MD

Blood (2012) 120 (21): 3005.

https://doi.org/10.1182/blood.V120.21.3005.3005

Published: 2012

Journal Articles

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

Koen M. Van Besien, MD, Wendy Stock, MD, Elizabeth Shima Rich, MD, PhD, Olatoyosi Odenike, MD, Lucy Godley, MD, PhD, Peter O'Donnell, MD, Justin Kline, MD, Vu H. Nguyen, MD, Paula Del Cerro, RN, Richard A. Larson, MD, Andrew Artz, MD MS

Blood (2011) 118 (21): 1948.

https://doi.org/10.1182/blood.V118.21.1948.1948

Published: 2011

Journal Articles

Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

Hongtao Liu, MD, PhD, Elizabeth Shima Rich, MD, PhD, Lucy Godley, MD, PhD, Olatoyosi Odenike, MD, Loren Joseph, M.D., Susana Marino, M.D., Justin Kline, MD, Vu H. Nguyen, MD, John M Cunningham, MD, Richard A. Larson, MD, Paula Del Cerro, RN, Linda Schroeder, RN, Lisa Pape, RN, Wendy Stock, MD, Amittha Wickrema, PhD, Andrew Artz, MD MS, Koen M. Van Besien, MD

Blood (2011) 118 (21): 830.

https://doi.org/10.1182/blood.V118.21.830.830

Published: 2011

Journal Articles

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes.

Koen van Besien, MD, Justin Kline, Lucy A Godley, MD, PhD, Richard A. Larson, MD, Vu H. Nguyen, MD, Olatoyosi Odenike, MD, Elizabeth Shima Rich, MD, PhD, Wendy Stock, MD, Amittha Wickrema, PhD, Scott Allen, BA, Paula del Cerro, Sarah Horowitz, Lisa Pape, RN, Linda Schroeder, RN, Andrew Artz, MD, MS

Blood (2009) 114 (22): 197.

https://doi.org/10.1182/blood.V114.22.197.197

Published: 2009

Journal Articles

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.

Elizabeth Shima Rich, MD, PhD, Andrew Artz, MD, MS, Theodore Karrison, Ph.D., Lucy A Godley, MD, PhD, Olatoyosi Odenike, MD, Loren Joseph, MD, Justin Kline, MD, Vu H. Nguyen, MD, Guadalupe Martinez, BS, Paula del Cerro, RN, Lisa Pape, RN, Linda Schroeder, RN, Scott Allen, BA, Sarah Horowitz, BA, John Cunningham, MD, Richard A. Larson, MD, Wendy Stock, MD, Amittha Wickrema, PhD, Koen van Besien, MD

Blood (2009) 114 (22): 3378.

https://doi.org/10.1182/blood.V114.22.3378.3378

Published: 2009

Journal Articles

Functional Comparison of Freshly Isolated and Ex-Vivo Expanded CD4+CD25+Foxp3+ Regulatory T Cells in Suppressing Murine Acute GvHD

Emanuela I Sega, PhD, Dennis Leveson-Gower, PhD, Vu H. Nguyen, MD, Robert Negrin, MD

Blood (2008) 112 (11): 812.

https://doi.org/10.1182/blood.V112.11.812.812

Published: 2008

Journal Articles

Allogeneic Environment and Tissue Damage Provide Critical Stimuli for Regulatory T Cell Expansion and Survival In Vivo after Hematopoietic Cell Transplantation.

Vu H. Nguyen, MD, Daisy Chang, BA, Robert S. Negrin, MD

Blood (2006) 108 (11): 1731.

https://doi.org/10.1182/blood.V108.11.1731.1731

Published: 2006

Journal Articles

CD4+CD25+ Regulatory T Cells Enhance Immune Reconstitution Following Allogeneic Hematopoietic Cell Transplantation by Protecting Thymic and Lymphoid Compartments from Graft-Versus-Host Disease Damage without Impacting T Cell Repertoire Development.

Vu H. Nguyen, MD, Daisy Chang, BA, Sumana Shashidhar, BA, Michael Bachmann, PhD, Christopher H. Contag, PhD, Janice M.Y. Brown, MD, Robert S. Negrin, MD

Blood (2006) 108 (11): 70.

https://doi.org/10.1182/blood.V108.11.70.70

Published: 2006

Journal Articles

Early Treatment with CD4+CD25+ Regulatory T Cells Provides Prolonged Suppressive Effects Which Control Evolving but Not Established Graft-Versus-Host-Disease.

Vu H. Nguyen, MD, Robert Zeiser, MD, Daniel Dasilva, BA, Christopher N. Contag, PhD, Robert S. Negrin, MD

Blood (2005) 106 (11): 1303.

https://doi.org/10.1182/blood.V106.11.1303.1303

Published: 2005

Journal Articles

Enhanced Immune Reconstitution and Function by CD4+CD25+ Regulatory T Cells Following Allogeneic Hematopoietic Cell Transplantation.

Vu H. Nguyen, MD, Sumana Shashidhar, BA, Robert Zeiser, MD, Lena Ho, BA, Janice M.Y. Brown, BA, Robert S. Negrin, MD

Blood (2005) 106 (11): 64.

https://doi.org/10.1182/blood.V106.11.64.64

Published: 2005

Journal Articles

In Vivo Trafficking of CD4+CD25+ Regulatory T-Cells in Allogeneic Recipients Using Bioluminescence Imaging.

Vu H. Nguyen, MD, Courtney Wieland, BA, Christopher Contag, PhD, Robert S. Negrin, MD

Blood (2004) 104 (11): 302.

https://doi.org/10.1182/blood.V104.11.302.302

Published: 2004

NARROW

Sequential Azacitidine and High-Dose Lenalidomide for Relapsed and Refractory High-Risk MDS and AML: Interim Analysis of a Phase 2 Study

Selected Commensals Mediate GvHD Via MyD88-Dependent Signaling in Non-Hematopoietic Cells.

Clofarabine-Melphalan-Alemtuzumab Conditioning for Allogeneic Hematopoietic Cell Transplantation: Final Report of a Phase I-II Study

Reduced Intensity Conditioning with Combined Haploidentical and Cord Blood Transplantation Results in Rapid Engraftment and Durable Remissions in Hematological Malignancies

Phase I-II Study of Clofarabine-Melphalan-Alemtuzumab (CMA) Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Advanced Hematologic Malignancies: Determination of MTD and Outcomes.

Allogeneic Hematopoietic Cell Transplantation From Combined Haploidentical Family Members and Unrelated Cord Blood (CB) Can Benefit High Risk Patients Lacking HLA-Identical Donors.

Functional Comparison of Freshly Isolated and Ex-Vivo Expanded CD4+CD25+Foxp3+ Regulatory T Cells in Suppressing Murine Acute GvHD

Allogeneic Environment and Tissue Damage Provide Critical Stimuli for Regulatory T Cell Expansion and Survival In Vivo after Hematopoietic Cell Transplantation.

CD4+CD25+ Regulatory T Cells Enhance Immune Reconstitution Following Allogeneic Hematopoietic Cell Transplantation by Protecting Thymic and Lymphoid Compartments from Graft-Versus-Host Disease Damage without Impacting T Cell Repertoire Development.

Early Treatment with CD4+CD25+ Regulatory T Cells Provides Prolonged Suppressive Effects Which Control Evolving but Not Established Graft-Versus-Host-Disease.

Enhanced Immune Reconstitution and Function by CD4+CD25+ Regulatory T Cells Following Allogeneic Hematopoietic Cell Transplantation.

In Vivo Trafficking of CD4+CD25+ Regulatory T-Cells in Allogeneic Recipients Using Bioluminescence Imaging.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only